Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802661 | 0.81 | L3MBTL1 (0.49) | IDO1MEN1LMNAHTTKMT2A | |
| SCHEMBL802289 | 0.80 | IDO1 (0.44) | IDO1MEN1LMNAHTTKMT2A | |
| SCHEMBL801654 | 0.74 | LATS1 (0.31) | MEN1LMNAHTTKMT2A | |
| SCHEMBL801624 | 0.73 | LATS1 (0.33) | LMNAHTT | |
| SCHEMBL802018 | 0.72 | JAK2 (0.34) | LRRK2SLC29A1IDO1MEN1LMNA | |
| SCHEMBL10266757 | 0.70 | LMNA (0.39) | LRRK2SLC29A1IDO1MEN1LMNA | |
| SCHEMBL801637 | 0.69 | APP (0.49) | MEN1LMNAHTTKMT2A | |
| SCHEMBL805583 | 0.69 | LRRK2 (0.36) | LRRK2SLC29A1LMNAHTTKMT2A | |
| SCHEMBL802648 | 0.68 | LATS1 (0.49) | LMNA | |
| SCHEMBL802291 | 0.68 | LATS1 (0.49) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | LRRK2 317/4885SLC29A1 2954/4885PDE10A 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.